Oruka Therapeutics, Inc. — Director's Dealing 2009

Mar 3, 2009

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: ARCA biopharma, Inc. (ABIO)
CIK: 0000907654
Period of Report: 2009-02-27

Reporting Person: ZABRISKIE JOHN L (Director)

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2009-02-27	Option to Purchase Common Stock	$5.29	A	7500	Acquired	2019-02-27	Common Stock (7500)	Direct

Footnotes

F1: The options vest ratably on a monthly basis over a two year period; full acceleration upon change in control and termination of service.